Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
01/1997
01/08/1997EP0751765A1 Sulfonamide derivatives and their use
01/08/1997EP0469075B1 Use of lipoxin a 4? and its derivatives as antagonists for slow-reacting substances of anaphylaxis
01/07/1997US5591851 Antiviral compounds
01/07/1997US5591761 Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
01/07/1997US5591755 Pyridinyl thiadiazolyl compounds for treating glaucoma
01/02/1997EP0751147A1 Toxoplasma gondii antigen, its production and use
01/02/1997EP0750614A1 Quinazolinyl-amino derivatives having alpha-antagonist activity
01/02/1997EP0750509A1 Use of il-12 and il-12 antagonists in the treatment of autoimmune diseases
01/01/1997CN1139384A Use of mometasone furoate for treating airway passage and lung diseases
12/1996
12/31/1996US5589487 Piperidine derivatives and process for their production
12/27/1996WO1996041795A1 Benzamide derivatives and their use as vasopressin antagonists
12/27/1996WO1996041645A1 Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
12/27/1996WO1996041626A1 Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
12/27/1996WO1996041625A1 Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
12/27/1996EP0749981A1 Monoclonal antibody
12/27/1996EP0749752A1 Use of specific RXR receptor ligands
12/27/1996EP0749428A1 Isoxazoline compounds as inhibitors of tnf release
12/27/1996EP0749307A1 Isoxazoline compounds as 5-lipoxygenase inhibitors
12/27/1996EP0749306A1 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
12/27/1996EP0749303A1 Method of treating disorders of the eye
12/27/1996EP0749302A1 Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
12/27/1996CA2224563A1 Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
12/27/1996CA2224517A1 Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
12/27/1996CA2224379A1 Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
12/27/1996CA2223869A1 Benzamide derivatives and their use as vasopressin antagonists
12/25/1996CN1138851A Metalloproteinase inhibitors
12/24/1996US5587479 Basic derivatives of glutamic acid and aspartic acid as gastrin or cholecystokinin antagonists
12/24/1996US5587391 Treating ocular hypertension
12/24/1996US5587376 Antiischemic agents, decongestants
12/24/1996US5587375 Azepinone compounds useful in the inhibition of ACE and NEP
12/20/1996CA2179426A1 Use of ligands specific to rxr receptors
12/19/1996WO1996040747A1 Urokinase receptor ligands
12/19/1996WO1996040647A1 α-(1,3-DICARBONYLENOL ETHER) METHYL KETONES AS CYSTEINE PROTEASE INHIBITORS
12/19/1996WO1996040636A1 Catechol diethers derivatives useful as pharmaceutical agents
12/19/1996WO1996040183A1 OCULAR THERAPY IN SJÖGREN'S SYNDROME USING TOPICALLY APPLIED ANDROGENS OR TGF-$g(b)
12/19/1996WO1996040169A1 Bacterial inhibition with an oligosaccharide compound
12/19/1996WO1996040116A1 Indolinone compounds for the treatment of disease
12/19/1996WO1996040104A1 Hydroxyl ions as unique therapeutic agents and compounds that modulate ions, compounds
12/19/1996WO1996040103A1 Treatment of a trabecular meshwork whose cells are subject ot inhibition of cell division with non-steroidal anti-inflammatory drugs
12/19/1996WO1996040102A1 Non-steroidal anti-inflammatory drugs for the cyto-protection of the trabecular meshwork
12/19/1996WO1996040094A1 Use of selegiline to treat hearing loss in mammals
12/19/1996DE19521684A1 Ophthalmic pharmaceutical composition
12/19/1996CA2224463A1 Ocular therapy in sjogren's syndrome using topically applied androgens or tgf-.beta.
12/19/1996CA2224102A1 Bacterial inhibition with an oligosaccharide compound
12/19/1996CA2223268A1 .alpha.-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
12/19/1996CA2222930A1 Treatment of a trabecular meshwork whose cells are subject to inhibition of cell division with non-steroidal anti-inflammatory drugs
12/19/1996CA2222929A1 Non-steroidal anti-inflammatory drugs for the cyto-protection of the trabecular meshwork
12/19/1996CA2196334A1 Urokinase receptor ligands
12/18/1996EP0748816A1 Toxoplasma gondii antigen, its production and use
12/18/1996EP0748815A1 Toxoplasma gondii antigen, its production and use
12/18/1996EP0748312A1 Bicyclic carbamates as leukotriene d4 antagonists
12/18/1996EP0748219A1 Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
12/18/1996EP0655059B1 Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension
12/18/1996CN1137917A Compound jiabing ear drops and preparation method thereof
12/17/1996US5585378 Can be administered for the prevention and treatment of cognitive dysfunctions
12/17/1996US5585355 Drug delivery with a bradykinin derivatives
12/17/1996US5585354 Suppressant of corneal subepithelial clouding
12/12/1996WO1996039515A1 Human vascular endothelial growth factor 2
12/12/1996WO1996039497A1 Transforming growth factor alpha hi
12/12/1996WO1996039485A1 Human hepatoma-derived growth factor-2
12/12/1996WO1996039408A1 TRICYCLIC 5,6-DIHYDRO-9H-PYRAZOLO[3,4-c]-1,2,4-TRIAZOLO[4,3-α]PYRIDINES
12/12/1996WO1996039154A1 Oligonucleotides having phosphorothioate linkages of high chiral purity
12/12/1996WO1996039147A2 Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases
12/12/1996WO1996039146A1 Non-irritation, non-sensitizing, non-ototoxic otic antibacterial compositions
12/12/1996WO1996034010A3 Inhibitors of farnesyl-protein transferase
12/12/1996WO1996020187A3 Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory products
12/12/1996WO1996011949A3 Analogs of keratinocyte growth factor
12/12/1996CA2223957A1 Transforming growth factor alpha hi
12/12/1996CA2223733A1 Human hepatoma-derived growth factor-2
12/12/1996CA2223103A1 Oligonucleotides having phosphorothioate linkages of high chiral purity
12/11/1996EP0747392A1 1,2-Diazepine containing dual action inhibitors
12/11/1996EP0747353A2 Indole derivatives
12/11/1996EP0747347A1 RARy-specific retinobenzoic acid derivatives
12/11/1996EP0747345A2 Ethylamido fluorenes and improved method of making same
12/11/1996CN1137794A 5-(2-imidazolinylamino) benzimidazole derivatives, their preparation and their use as alpha-2 adrenoceptor agonists
12/11/1996CN1137793A 6-(2-imidzolinylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
12/11/1996CN1137755A 6-(2-imidazolinylamino) quinoxaling compounds useful as alpha-2 adrenoceptor agonists
12/11/1996CN1137754A 7-(2-imidazolinylamino) quinoline compounds as alpha-2 adrenoceptor agonists
12/10/1996US5583152 Method for treating vasospastic cardiovascular diseases heterocyclic amide derivatives
12/10/1996CA1338777C Methods and compositions for preventing secondary cataracts
12/08/1996CA2178355A1 Diazepine containing dual action inhibitors
12/07/1996CA2175854A1 Rar(gamma)-specific retinobenzoic acid derivatives
12/05/1996WO1996038548A1 Oxygen activatable formulations for disinfection or sterilization
12/05/1996WO1996038457A1 Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
12/05/1996WO1996038426A1 Novel isoxazoline and isoxazole fibrinogen receptor antagonists
12/05/1996WO1996038172A1 Connective tissue growth factor
12/05/1996WO1996038168A1 Methods and uses of connective tissue growth factor as an induction agent
12/05/1996CA2223276A1 Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
12/05/1996CA2222609A1 Methods and uses of connective tissue growth factor as an induction agent
12/05/1996CA2222147A1 Novel isoxazoline and isoxazole fibrinogen receptor antagonists
12/04/1996EP0745391A1 Apparatus, method and composition for preserving media in tip of solution dispenser
12/04/1996EP0745092A1 Peptide inhibitors of urokinase receptor activity
12/04/1996EP0745081A1 Novel indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase
12/04/1996EP0745080A1 Novel mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace
12/03/1996US5581011 Antihistamine intermediates
12/03/1996US5580878 Treating sleep disorders
12/03/1996US5580555 Administering tumor necrosis factor and irradiating with low energy laser
12/03/1996CA2075833C Neuropeptide control of ocular growth
12/01/1996CA2177538A1 Apparatus, method and composition for preserving media in tip of solution dispenser
11/1996
11/28/1996WO1996037489A1 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists
1 ... 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 ... 531